AMSBIO has announced a new 5-Clone Collagen Antibody-Induced Arthritis (CIAA) kit for the induction of Collagen-Induced Arthritis (CIA) in various species.
Collagen Antibody-Induced Arthritis (CAIA) has been widely used since 1998 when 4-clone cocktail (Arthrogen-CIA® arthritogenic monoclonal antibodies) kits first appeared. In order to induce consistent arthritis more effectively in various mouse strains including CAIA low responder C57BL/6 mice, and a variety of unpredictable knockout and transgenic mice with C57BL/6 (H-2b) or 129/Sv (H-2b) backgrounds, a new 5-clone cocktail kits have been developed by adding a new clone to the 4-clone cocktail.
The new 5-Clone CIAA produces faster results: Typically severe arthritis is induced within 24–48 hours instead of the four weeks required to induce CIA after immunization with type II collagen. Unlike the original CIA model, which requires a restricted MHC haplotype, the new 5-Clone CAIA model is broadly applicable and can induce arthritis in almost all strains of mice, including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice. Beneficially the new 5-Clone kits offer excellent consistency meaning the severity of arthritis induced now directly correlates to the dose of monoclonal antibody cocktail, and more severe and consistent arthritis can be induced by increasing the dose of monoclonal antibody cocktail. Therefore, this model is ideal for studying the pathological role of individual gene products, cytokines, as well as screening and evaluating anti-inflammatory agents without influences of complete or incomplete Freund's adjuvant, which strongly affects the host's immune system.
AMSBIO also offer a wide range of various species and types of highly purified cartilage collagen, type II, IX, and XI collagen together with different Freund’s Adjuvants to study Collagen Induced Arthritis.
For further information please visit http://www.amsbio.com/Collagen-Antibody-Induced-Arthritis.aspx or contact AMSBIO on +44-1235-828200 / [email protected].
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.